Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 9INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 13Gastrointestinal 9Breast 9Other hematologic neoplasm 7Thoracic 6Plasma cell 6Lymphoid 5Tumor-Agnostic 4Head & Neck 4Gynecologic 4CNS 4Dermatologic 2Sarcoma 1Other solid neoplasm 1Myeloid 1Classical hematology 1

Conditions

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion 1

Interventions

Doxorubicin 44Imatinib Mesylate 33pembrolizumab 23Cyclophosphamide 23Sunitinib 22Gemcitabine 22Temozolomide 17Irinotecan 14Bevacizumab 14Docetaxel 13nilotinib 12Trabectedin 12ripretinib 11pazopanib 11olaratumab 10fludarabine 10eribulin 10regorafenib 9avapritinib 9Fluorouracil 9Carboplatin 9Paclitaxel 8Nivolumab 8Ifosfamide 8Ibandronic Acid 8spartalizumab 7anlotinib 7Vincristine 7Radiation 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Standard of Care × Sarcoma × Clear all
NCT05236257 2024-12-10

EPI VITRAKVI

Bayer

Completed
93 enrolled 14 charts
Sarcoma

Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡